Program: Oral and Poster Abstracts
Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Poster III
Methods: Patient demographics, ASBMT disease risk classification, relapse and mortality data for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients undergoing MRD, MUD, and HC SCT between 1/2012-1/2015 were included. Time until TI for RBC and PLT was defined as the day of the last transfusion with no transfusions in the following 30 days (d). The cohorts were followed for 180d post-transplant. Kaplan-Meier survival method was used to compare time until RBC and PLT transfusion independence between different transplant types and ASBMT risk categories. Data were censored on disease relapse or death. Log-rank test was used to compare the survival probabilities. Statistical analyses were performed using SAS 9.4.0 (SAS Institute, Cary, NC).
Results: A total of 194 AML/MDS patients received MRD (n=63, 32%), MUD (n=76, 39%), and HC (n=55, 28%) SCT. TI was achieved for RBC transfusion in 84%, 74%, and 67% of patients, and for PLT transfusion in 84%, 91%, and 85% of patients for MRD, MUD, and HC respectively. The time to attain RBC and PLT TI was not statistically different between HC and MUD transplants (log-rank p=0.16 and 0.09 respectively) (Fig. 1: A, C). Within the ASBMT high risk strata, no statistical differences in the time to attain RBC (log-rank p=0.15) and PLT (log-rank p=0.55) TI between any transplant types could be detected (Fig. 1: B, D).
Conclusion: Recipients of SCT often have substantial transfusion requirements. No statistically significant difference in time to TI was seen between HC and MUD recipients. No statistically significant differences in time to TI were seen between HC, MUD and MRD recipients in the ASBMT high risk strata. Time until transfusion independence in haplo-cord transplant is comparable to matched unrelated stem cell transplant.
Figure 1.
Disclosures: van Besien: Miltenyi Biotec: Research Funding .
See more of: Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities
See more of: Oral and Poster Abstracts
*signifies non-member of ASH